Dupilumab Shows Promise in Rare Eosinophilic Gastritis Trial
Event summary
- Phase 2 trial of dupilumab in eosinophilic gastritis (EoG) shows significant improvements in stomach tissue and safety profile.
- Study involved 41 teens and adults across 11 U.S. centers, led by Cincinnati Children's Hospital Medical Center.
- Dupilumab, already approved for atopic dermatitis and eosinophilic esophagitis, demonstrates potential for repurposing in rare diseases.
- Findings published June 23, 2026, in The Lancet Gastroenterology & Hepatology.
The big picture
The successful repurposing of dupilumab for eosinophilic gastritis highlights a strategic model for addressing rare diseases with existing therapies. This approach could accelerate treatment development for conditions lacking dedicated pharmaceutical investment, leveraging established safety profiles to bypass early-stage clinical hurdles. The trial's collaborative structure through the NIH-supported CEGIR network demonstrates how academic-industry partnerships can efficiently advance orphan drug research.
What we're watching
- Regulatory Pathway
- Whether the FDA will prioritize approval for dupilumab in EoG given the challenges of studying rare diseases.
- Market Expansion
- The pace at which Regeneron and Sanofi can leverage this data to expand dupilumab's indications beyond current approvals.
- Clinical Translation
- How tissue-level improvements observed in the trial will translate into long-term symptom relief for EoG patients.
Related topics